WO2025233865 - ENPP1 INHIBITORS
National phase entry is expected:
Publication Number
WO/2025/233865
Publication Date
13.11.2025
International Application No.
PCT/IB2025/054805
International Filing Date
07.05.2025
Title **
[English]
ENPP1 INHIBITORS
[French]
INHIBITEURS D'ENPP1
Applicants **
RE VENTURES I, LLC
Inventors
BELL, Andrew Simon
BESNARD, Jeremy
CHEMI, Giulia
BARBEAU, Olivier Rémi
PÉREZ, Víctor Sebastián
Priority Data
2406317.4
07.05.2024
GB
2413624.4
16.09.2024
GB
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4004 | |
| EPO | Filing, Examination, Granting | 24406 | |
| Japan | Filing, Examination, Granting | 2856 | |
| South Korea | Filing, Examination, Granting | 3425 | |
| USA | Filing, Examination, Granting | 16690 |
Total:
51,381
Contact Us
Abstract[English]
Disclosed are compounds, compositions and methods for treating disease, syndromes, conditions and disorders that are affected by the inhibition of ENPP1. Such compounds are represented by Formula (I), wherein the variables are defined herein.[French]
L'invention concerne des composés, des compositions et des méthodes pour le traitement d'une maladie, de syndromes, d'états et de troubles sur lesquels l'inhibition d'ENPP1 a une influence. De tels composés sont représentés par la formule (I), les variables étant définies dans la description.